Cover Image
市場調查報告書

頭部、頸部的復發性鱗狀細胞癌:開發中產品分析

Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 253670
出版日期 內容資訊 英文 199 Pages
訂單完成後即時交付
價格
Back to Top
頭部、頸部的復發性鱗狀細胞癌:開發中產品分析 Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015
出版日期: 2015年10月30日 內容資訊: 英文 199 Pages
簡介

所謂頭部、頸部的復發性鱗狀細胞癌,是指最初治療後再次出現的腫瘤。主要的症狀為鼻血、頭痛的頻繁發生、眼球腫起來和其他症狀、上牙的疼痛和假牙的故障、耳鳴、牙齦/舌頭/口腔粘膜等出現白色/紅色的斑點等。易罹病素質中,包含年齡和家族病史,抽煙,對化學藥品、有毒氣體的暴露等。主要的治療方法有化療和放射治療、外科手術等。

本報告提供全球各國的頭部、頸部的復發性鱗狀細胞癌治療用的開發中產品的開發情形相關分析、產品開發、上市的最新趨勢,及臨床實驗各階段的產品一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等資訊,為您概述為以下內容。

簡介

  • 調查範圍

頭部、頸部的復發性鱗狀細胞癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

頭部、頸部的復發性鱗狀細胞癌:企業開發中的治療藥

頭部、頸部的復發性鱗狀細胞癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

頭部、頸部的復發性鱗狀細胞癌:企業開發中的產品

頭部、頸部的復發性鱗狀細胞癌治療藥的開發企業

  • Advaxis, Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Critical Outcome Technologies Inc.
  • 第一三共
  • Genentech, Inc.
  • Glycotope GmbH
  • Immunovative Therapies, Ltd.
  • Laboratoires Pierre Fabre SA
  • Mabion SA
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Oncolytics Biotech Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Panacea Biotec Limited
  • PCI Biotech AS
  • 鹽野義製藥
  • Symphogen A/S
  • Threshold Pharmaceuticals, Inc.
  • VentiRx Pharmaceuticals, Inc.

頭部、頸部的復發性鱗狀細胞癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

頭部、頸部的復發性鱗狀細胞癌:最近的開發平台趨勢

頭部、頸部的復發性鱗狀細胞癌:暫停中的計劃

頭部、頸部的復發性鱗狀細胞癌:開發中止的產品

頭部、頸部的復發性鱗狀細胞癌:產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7252IDB

Summary

Global Markets Direct's, 'Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015', provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Recurrent Head And Neck Cancer Squamous Cell Carcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Recurrent Head and Neck Cancer Squamous Cell Carcinoma Overview
  • Therapeutics Development
    • Pipeline Products for Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Overview
    • Pipeline Products for Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Comparative Analysis
  • Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies
  • Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies
  • Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development
    • Advaxis, Inc.
    • Amgen Inc.
    • AstraZeneca Plc
    • AVEO Pharmaceuticals, Inc.
    • Critical Outcome Technologies Inc.
    • Daiichi Sankyo Company, Limited
    • Genentech, Inc.
    • Glycotope GmbH
    • Immunovative Therapies, Ltd.
    • Laboratoires Pierre Fabre SA
    • Mabion SA
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Novartis AG
    • Oncolytics Biotech Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Panacea Biotec Limited
    • PCI Biotech AS
    • Shionogi & Co., Ltd.
    • Symphogen A/S
    • Threshold Pharmaceuticals, Inc.
    • VentiRx Pharmaceuticals, Inc.
  • Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AdIL-24 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AlloVax - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alpelisib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • axalimogene filolisbac - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZD-5069 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZD-9150 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bleomycin sulfate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cetuximab biobetter - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cetuximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cetuximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cetuximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • COTI-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • duligotuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • durvalumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • durvalumab + tremelimumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • elgemtumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ficlatuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • futuximab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • motolimod - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • panitumumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • patritumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pelareorep - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-488210 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tarloxotinib bromide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vinflunine ditartrate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones
    • Featured News & Press Releases
      • Aug 27, 2015: Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2015
  • Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd...1)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd...1)
  • Products under Development by Companies, H2 2015 (Contd...2)
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Advaxis, Inc., H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca Plc, H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc., H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genentech, Inc., H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA, H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA, H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech AS, H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S, H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H2 2015
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top